To eat or not to eat: Dietary fat in uremia is the question

Seminars in Dialysis

Volumn 23, Issue 4, 2010, Pages 383-388

  Axelsson, Thiane Gama ^a   Irving, Gerd Faxén ^a   Axelsson, Jonas ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

TRIACYLGLYCEROL;

ARTICLE; CARDIOVASCULAR DISEASE; DIET; DIET THERAPY; DYSLIPIDEMIA; EATING; FAT INTAKE; HUMAN; METABOLISM; METHODOLOGY; RISK FACTOR; UREMIA;

CARDIOVASCULAR DISEASES; DIET; DIETARY FATS; DYSLIPIDEMIAS; EATING; HUMANS; RISK FACTORS; TRIGLYCERIDES; UREMIA;

EID: 77955247487     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2010.00747.x     Document Type: Article

References (78)

1. Kopple JD, Berg R, Houser H, Steinman TI, Teschan P. Nutritional status of patients with different levels of chronic renal insufficiency. Modification of Diet in Renal Disease (MDRD) Study Group. Kidney Int Suppl 1989, 27:S184-S194.
2. Fouque D, Laville M. Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database Syst Rev 2009, (3):CD001892.
3. de Boer IH, Katz R, Fried LF, Ix JH, Luchsinger J, Sarnak MJ, Shlipak MG, Siscovick DS, Kestenbaum B. Obesity and change in estimated GFR among older adults. Am J Kidney Dis 2009, 54(6):1043-1051.
4. Maclaughlin HL, Cook SA, Kariyawasam D, Roseke M, van Niekerk M, Macdougall IC. Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up. Am J Kidney Dis 2009
5. Navaneethan SD, Yehnert H, Moustarah F, Schreiber MJ, Schauer PR, Beddhu S. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009, 4(10):1565-1574.
6. Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L, Franch H, Guarnieri G, Ikizler TA, Kaysen G, Lindholm B, Massy Z, Mitch W, Pineda E, Stenvinkel P, Trevino-Becerra A, Wanner C. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008, 73(4):391-398.
7. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA 1987, 257(16):2176-2180.
8. Jakobsen MU, O'Reilly EJ, Heitmann BL, Pereira MA, Balter K, Fraser GE, Goldbourt U, Hallmans G, Knekt P, Liu S, Pietinen P, Spiegelman D, Stevens J, Virtamo J, Willett WC, Ascherio A. Major types of dietary fat and risk of coronary heart disease: a pooled analysis of 11 cohort studies. Am J Clin Nutr 2009, 89(5):1425-1432.
9. Laaksonen DE, Nyyssonen K, Niskanen L, Rissanen TH, Salonen JT. Prediction of cardiovascular mortality in middle-aged men by dietary and serum linoleic and polyunsaturated fatty acids. Arch Intern Med 2005, 165(2):193-199.
10. Bray GA, Popkin BM. Dietary fat intake does affect obesity!. Am J Clin Nutr 1998, 68(6):1157-1173.
11. York DA, Rossner S, Caterson I, Chen CM, James WP, Kumanyika S, Martorell R, Vorster HH. Prevention Conference VII: obesity, a worldwide epidemic related to heart disease and stroke: Group I: worldwide demographics of obesity. Circulation 2004, 110(18):e463-e470.
12. Meguid El, Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005, 365(9456):331-340.
13. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, Sarnak MJ. The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol 2007, 50(3):217-224.
14. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008, 3(2):505-521.
15. Olarte IG, Hawasli A. Kidney transplant complications and obesity. Am J Surg 2009, 197(3):424-426.
16. Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome. J Am Soc Nephrol 2007, 18(1):304-311.
17. Kilpatrick RD, McAllister CJ, Kovesdy CP, Derose SF, Kopple JD, Kalantar-Zadeh K. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 2007, 18(1):293-303.
18. Tschope W, Koch M, Thomas B, Ritz E. Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis. Results of a prospective study. The German Study Group Diabetes and Uremia. Nephron 1993, 64(3):354-358.
19. Chmielewski M, Carrero JJ, Qureshi AR, Axelsson J, Heimburger O, Berglund L, Barany P, Rutkowski B, Lindholm B, Stenvinkel P. Temporal discrepancies in the association between the apoB/apoA-I ratio and mortality in incident dialysis patients. J Intern Med 2009, 265(6):708-716.
20. Kaysen GA. Lipid and lipoprotein metabolism in chronic kidney disease. J Ren Nutr 2009, 19(1):73-77.
21. Goldwasser P, Michel MA, Collier J, Mittman N, Fein PA, Gusik SA, Avram MM. Prealbumin and lipoprotein(a) in hemodialysis: relationships with patient and vascular access survival. Am J Kidney Dis 1993, 22(1):215-225.
22. Fuh MM, Lee CM, Jeng CY, Shen DC, Shieh SM, Reaven GM, Chen YD. Effect of chronic renal failure on high-density lipoprotein kinetics. Kidney Int 1990, 37(5):1295-1300.
23. Vaziri ND, Liang K, Parks JS. Down-regulation of hepatic lecithin: cholesterol acyltransferase gene expression in chronic renal failure. Kidney Int 2001, 59(6):2192-2196.
24. Axelsson J, Rashid Qureshi A, Suliman ME, Honda H, Pecoits-Filho R, Heimburger O, Lindholm B, Cederholm T, Stenvinkel P. Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr 2004, 80(5):1222-1229.
25. Moradi H, Yuan J, Ni Z, Norris K, Vaziri ND. Reverse cholesterol transport pathway in experimental chronic renal failure. Am J Nephrol 2009, 30(2):147-154.
26. Yvan-Charvet L, Wang N, Tall AR. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol 2009
27. Cordeiro AC, Qureshi AR, Stenvinkel P, Heimburger O, Axelsson J, Barany P, Lindholm B, Carrero JJ. Abdominal fat deposition is associated with increased inflammation, protein-energy wasting and worse outcome in patients undergoing haemodialysis. Nephrol Dial Transplant 2009
28. Avesani CM, Draibe SA, Kamimura MA, Dalboni MA, Colugnati FA, Cuppari L. Decreased resting energy expenditure in non-dialysed chronic kidney disease patients. Nephrol Dial Transplant 2004, 19(12):3091-3097.
29. Avesani CM, Draibe SA, Kamimura MA, Colugnati FA, Cuppari L. Resting energy expenditure of chronic kidney disease patients: influence of renal function and subclinical inflammation. Am J Kidney Dis 2004, 44(6):1008-1016.
30. Wang AY, Sea MM, Tang N, Sanderson JE, Lui SF, Li PK, Woo J. Resting energy expenditure and subsequent mortality risk in peritoneal dialysis patients. J Am Soc Nephrol 2004, 15(12):3134-3143.
31. Monteon FJ, Laidlaw SA, Shaib JK, Kopple JD. Energy expenditure in patients with chronic renal failure. Kidney Int 1986, 30:741-747.
32. Avesani CM, Kamimura MA, Draibe SA, Cuppari L. Is energy intake underestimated in nondialyzed chronic kidney disease patients? J Ren Nutr 2005, 15(1):159-165.
33. Axelsson J, Bergsten A, Qureshi AR, Heimburger O, Barany P, Lonnqvist F, Lindholm B, Nordfors L, Alvestrand A, Stenvinkel P. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int 2006, 69(3):596-604.
34. Sechi LA, Catena C, Zingaro L, Melis A, De Marchi S. Abnormalities of glucose metabolism in patients with early renal failure. Diabetes 2002, 51(4):1226-1232.
35. Charlesworth JA, Kriketos AD, Jones JE, Erlich JH, Campbell LV, Peake PW. Insulin resistance and postprandial triglyceride levels in primary renal disease. Metabolism 2005, 54(6):821-828.
36. Prinsen BH, de Sain-van der Velden MG, de Koning EJ, Koomans HA, Berger R, Rabelink TJ. Hypertriglyceridemia in patients with chronic renal failure: possible mechanisms. Kidney Int Suppl 2003, (84):S121-S124.
37. Axelsson J. The emerging biology of adipose tissue in chronic kidney disease: from fat to facts. Nephrol Dial Transplant 2008, 23(10):3041-3046.
38. Kent PS. Integrating clinical nutrition practice guidelines in chronic kidney disease. Nutr Clin Pract 2005, 20(2):213-217.
39. Ikizler TA. Dietary protein restriction in CKD: the debate continues. Am J Kidney Dis 2009, 53(2):189-191.
40. KDOQI Clinical Practice Guideline for nutrition in children with CKD 2008 update. Executive summary. Am J Kidney Dis 2009, 53(3 Suppl. 2):S11-S104.
41. Kris-Etherton PM, Innis S. Position of the American Dietetic Association and Dietitians of Canada: dietary fatty acids. J Am Diet Assoc 2007, 107(9):1599-1611.
42. Ewers B, Riserus U, Marckmann P. Effects of unsaturated fat dietary supplements on blood lipids, and on markers of malnutrition and inflammation in hemodialysis patients. J Ren Nutr 2009, 19(5):401-411.
43. de Mutsert R, Grootendorst DC, Indemans F, Boeschoten EW, Krediet RT, Dekker FW. Association between serum albumin and mortality in dialysis patients is partly explained by inflammation, and not by malnutrition. J Ren Nutr 2009, 19(2):127-135.
44. Axelsson J, Moller HJ, Witasp A, Qureshi AR, Carrero JJ, Heimburg-er O, Barany P, Alvestrand A, Lindholm B, Moestrup SK, Stenvinkel P. Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD. Am J Kidney Dis 2006, 48(6):916-925.
45. Honda H, Qureshi AR, Axelsson J, Heimburger O, Suliman ME, Barany P, Stenvinkel P, Lindholm B. Obese sarcopenia in patients with end-stage renal disease is associated with inflammation and increased mortality. Am J Clin Nutr 2007, 86(3):633-638.
46. Stenvinkel P, Lindholm B. Resolved: being fat is good for dialysis patients: the Godzilla effect: con. J Am Soc Nephrol 2008, 19(6):1062-1064.
47. Ikizler TA. Resolved: being fat is good for dialysis patients: the Godzilla effect: pro. J Am Soc Nephrol 2008, 19(6):1059-1062.
48. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003, 63(3):793-808.
49. Beddhu S. The body mass index paradox and an obesity, inflammation, and atherosclerosis syndrome in chronic kidney disease. Semin Dial 2004, 17(3):229-232.
50. Kwan BC, Beddhu S. A story half untold: adiposity, adipokines and outcomes in dialysis population. Semin Dial 2007, 20(6):493-497.
51. Ahima RS, Lazar MA. Adipokines and the peripheral and neural control of energy balance. Mol Endocrinol 2008, 22(5):1023-1031.
52. Beddhu S, Kimmel PL, Ramkumar N, Cheung AK. Associations of metabolic syndrome with inflammation in CKD: results from the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2005, 46(4):577-586.
53. Park SH, Lindholm B. Definition of metabolic syndrome in peritoneal dialysis. Perit Dial Int 2009, 29(Suppl. 2):S137-S144.
54. Kalantar-Zadeh K, Abbott KC, Salahudeen AK, Kilpatrick RD, Horwich TB. Survival advantages of obesity in dialysis patients. Am J Clin Nutr 2005, 81(3):543-554.
55. Madero M, Sarnak MJ, Wang X, Sceppa CC, Greene T, Beck GJ, Kusek JW, Collins AJ, Levey AS, Menon V. Body mass index and mortality in CKD. Am J Kidney Dis 2007, 50(3):404-411.
56. Beddhu S, Pappas LM, Ramkumar N, Samore MH. Effects of body size and body composition on survival in hemodialysis patients. J Am Soc Nephrol 2003, 14:2366-2372.
57. de Mutsert R, Snijder MB, van der Sman-de Beer F, Seidell JC, Boeschoten EW, Krediet RT, Dekker JM, Vandenbroucke JP, Dekker FW. Association between body mass index and mortality is similar in the hemodialysis population and the general population at high age and equal duration of follow-up. J Am Soc Nephrol 2007, 18(3):967-974.
58. Postorino M, Marino C, Tripepi G, Zoccali C. Abdominal obesity and all-cause and cardiovascular mortality in end-stage renal disease. J Am Coll Cardiol 2009, 53(15):1265-1272.
59. Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008, 9(5):367-377.
60. Kwan BC, Murtaugh MA, Beddhu S. Associations of body size with metabolic syndrome and mortality in moderate chronic kidney disease. Clin J Am Soc Nephrol 2007, 2(5):992-998.
61. Lee DM, Knight-Gibson C, Samuelsson O, Attman PO, Wang CS, Alaupovic P. Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency. Kidney Int 2002, 61(1):209-218.
62. Marchlewska A, Stenvinkel P, Lindholm B, Danielsson A, Pecoits- Filho R, Lonnqvist F, Schalling M, Heimburger O, Nordfors L. Reduced gene expression of adiponectin in fat tissue from patients with end-stage renal disease. Kidney Int 2004, 66(1):46-50.
63. Heimburger O, Lonnqvist F, Danielsson A, Nordenstrom J, Stenvinkel P. Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. J Am Soc Nephrol 1997, 8(9):1423-1430.
64. Nordfors L, Lonnqvist F, Heimburger O, Danielsson A, Schalling M, Stenvinkel P. Low leptin gene expression and hyperleptinemia in chronic renal failure. Kidney Int 1998, 54(4):1267-1275.
65. Huang M, LaLuzerne P, Winters D, Sullivan D. Measurement of vitamin D in foods and nutritional supplements by liquid chromatography/tandem mass spectrometry. J AOAC Int 2009, 92(5):1327-1335.
66. Gao X, Martin A, Lin H, Bermudez OI, Tucker KL. α-Tocopherol intake and plasma concentration of Hispanic and non-Hispanic white elders is associated with dietary intake pattern. J Nutr 2006, 136(10):2574-2579.
67. Ribaya-Mercado JD. Influence of dietary fat on beta-carotene absorption and bioconversion into vitamin A. Nutr Rev 2002, 60(4):104-110.
68. Mizobuchi M, Ogata H, Koiwa F, Kinugasa E, Akizawa T. Vitamin D and vascular calcification in chronic kidney disease. Bone 2009, 45(Suppl. 1):S26-S29.
69. Axelsson J, O'Byrne SM, Blaner WS, Carrero JJ, Bruchfeld A, Heim-burger O, Barany P, Lindholm B, Stenvinkel P. Serum retinol-binding protein concentration and its association with components of the uremic metabolic syndrome in nondiabetic patients with chronic kidney disease stage 5. Am J Nephrol 2009, 29(5):447-453.
70. Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckel-baum RJ, Erdman JW, Kris-Etherton P, Goldberg IJ, Kotchen TA, Lichtenstein AH, Mitch WE, Mullis R, Robinson K, Wylie-Rosett J, St Jeor S, Suttie J, Tribble DL, Bazzarre TL. AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 2000, 102(18):2284-2299.
71. Arslan Y, Kiziltan G. Nutrition-related cardiovascular risk factors in hemodialysis patients. J Ren Nutr 2009
72. Sarzani R, Salvi F, Dessi-Fulgheri P, Rappelli A. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens 2008, 26(5):831-843.
73. Cheung W, Yu PX, Little BM, Cone RD, Marks DL, Mak RH. Role of leptin and melanocortin signaling in uremia-associated cachexia. J Clin Invest 2005, 115(6):1659-1665.
74. Gadegbeku CA, Shrayyef MZ, LaPorte FB, Egan BM. Lipids enhance alpha1-adrenoceptor pressor sensitivity in patients with chronic kidney disease. Am J Kidney Dis 2004, 44(3):446-454.
75. Rigalleau V, Gin H. Carbohydrate metabolism in uraemia. Curr Opin Clin Nutr Metab Care 2005, 8(4):463-469.
76. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353(3):238-248.
77. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SW, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009, 360(14):1395-1407.
78. Cano NJ, Miolane-Debouit M, Leger J, Heng AE. Assessment of body protein: energy status in chronic kidney disease. Semin Nephrol 2009, 29(1):59-66.